Shares at this price are a screaming bargain. We have three...

Shares at this price are a screaming bargain. We have three programmes which are largely de-risked, and a good chance to be best in class and in markets totalling above $50B; that is billion with a B.
Zafirulkast is a drug previously proven by Astra Zeneca as safe and effective as a treatment for acute asthma in an inhaled delivery format. The programme was discontinued as they were using CFCs as a propellant and they were banned in the "hole in the ozone layer" hysteria. They could not develop a suitable alternative form of delivery. Invion has partnered with Hovione who are world leaders in drug formulation and have a patented delivery system for inhaled delivery. They would not have signed an agreement unless they already had the delivery system solved or were supremely confident of doing so. This is a market worth probably of the order of $10B. The current treatment is largely corticosteroids which are pretty nasty drugs and not really recommended for children if they can be avoided.
The recently released results in smoking cessation trials in oral Nadolol were sensational; nearly a doubling of positive results in the patients receiving Nadilol over placebo. There is no question of safety. This is a $3.8B market. These results also largely de-risk the inhaled programme in this drug. The partnership with 3 M seems to have already solved any problems with delivery by the inhaled method. This is the only drug on the horizon which looks like actually healing the lung as opposed to treating symptoms. This is a $30B market. Then we have Cpn10. This has been hypothesised as one of five RAMPs to act as control in all auto-immune diseases. It has very good results in trials in Lupus and other indications. It has shown safety in over 300 patients and dose response in recent trials. It is really still an early stage drug and requires substantial funds to advance it further, which is, no doubt, why the Company has promoted it as a partnering opportunity. However we own the molecule and it is at least five years ahead of any other RAMP. It is a valuable property, as a potential treatment for the whole range of auto-immune diseases.
Any rational fundamental valuation will come in ahead of $1.00. On a risk/reward calculation, you will not see a better opportunity in your lifetime.